Glenmark Pharmaceuticals is set to become net cash positive through its licensing agreement with AbbVie Inc. This move aims ...

Glenmark, through wholly-owned subsidiary IGI Therapeutics SA, announced an exclusive licensing agreement with AbbVie for ISB ...

Choice Institutional Equities has reiterated its positive stance on Glenmark Pharma following a major licensing deal between ...

Pharma giants like Cipla, Glenmark, and Emcure are stepping into the booming skincare market, challenging beauty brands with ...

Glenmark Pharma's licensing deal with AbbVie will make it cash positive, improving its financial position and liquidity, according to S&P.

By Kashish Tandon (Reuters) -Shares of India's Glenmark Pharmaceuticals jumped 10% to a record high on Friday, a day after ...

Glenmark’s outlicensing deal with AbbVie for a novel drug for blood cancer under development sets a new course for the ...

Glenmark Pharmaceuticals Ltd is quoting at Rs 2235, up 0.4% on the day as on 12:44 IST on the NSE. The stock is up 58.13% in last one year as compared to a 1.63% gain in NIFTY and a 8.9% gain in the ...

An analyst from Anand Rathi said that BHEL is encountering strong resistance in the Rs 265–270 zone, which coincides with its ...

A warning letter is a serious communication from the USFDA that signifies a potential risk to public health or safety due to ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

With a $2-billion cancer drug deal in its pocket, Glenmark’s licensing agreement with AbbVie not only unlocks a potential ...